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Abstract: Various factors may confound how diabetes medications affect a patient’s weight. 
Agents that induce hypoglycemia may promote weight gain through “defensive eating”. Con-
versely, patients whose hyperglycemia exceeds the renal glucose threshold may overeat to 
compensate for calories lost in urine and so gain weight when drug therapy ablates glycosuria. 
Some drugs, such as thiazolidinediones, may promote weight gain via increased lipid storage. 
Glucagon-like peptide-1 receptor agonists increase satiety, delay gastric emptying, and gener-
ally produce weight loss. Dipeptidyl peptidase (DPP)-4 inhibitors are generally weight-neutral, 
although modest weight loss has been observed with the DPP-4 inhibitor, vildagliptin, in patients 
with relatively low baseline glycemia. The weight neutrality of vildagliptin likely results in part 
from its intrinsically low risk for hypoglycemia. Recent studies point to additional potential 
mechanisms. One study found that drug-naïve patients randomized to vildagliptin exhibited 
significantly lower chylomicron lipid and apolipoprotein levels than placebo patients, sug-
gesting that vildagliptin may inhibit intestinal fat extraction. Another trial found that patients 
randomized to vildagliptin versus placebo experienced paradoxical postprandial increases in 
markers of fatty acid mobilization and oxidation, in conjunction with increased sympathetic 
stimulation. Elaboration of these and other pathways could further clarify the origins of the 
favorable weight profile of vildagriptin.
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Introduction
Overweight and/or obesity contribute to the risk of developing type 2 diabetes, and 
confound glycemic control once the disease develops.1 Interventions aimed at weight 
loss are recommended for the estimated 80%–90% of patients with type 2 diabe-
tes whose weight exceeds normal.2–4 In such patients, successful weight loss can 
improve glycemic control, as well as reduce concomitant cardiovascular risk factors, 
eg, hypertension and dyslipidemia.1 Clinicians therefore need to pay close attention 
to the effects of diabetes therapies on body weight and adiposity.
In general terms, the potential effects of various antidiabetic drug classes 
on weight balance are well recognized. Both insulin and insulin secretagogues 
(  sulfonylureas and glinides) promote weight gain, especially in regimens designed 
to achieve intensive glycemic control. Thiazolidinediones (TZDs) are associated 
with weight gain, while metformin is generally associated with weight neutrality 
or weight loss. Incretin-based therapies, including glucagon-like peptide (GLP)-1 
receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors, are associated with 
weight loss or weight neutrality.1Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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A more detailed appreciation of how diabetes   medications 
may affect a patient’s weight, and the implications of such 
interactions on key factors including insulin sensitivity, 
requires consideration of various confounding factors. These 
factors include compensatory mechanisms that come into 
play at glycemic extremes (calorie wasting in hyperglycemia 
and defensive eating at the cusp of hypoglycemia), as well as 
the effects of specific treatments on lipid metabolism. This 
article examines the role of these and other factors, with a 
special focus on the weight neutrality of the DPP-4 inhibitor 
vildagliptin.
Body weight and glycemic control
Obesity contributes to an individual’s risk of type 2 diabetes, 
largely through its contribution to insulin resistance.5 Large 
fat cells resist insulin-mediated lipolysis suppression, resulting 
in excess free fatty acid (FFA) release. FFAs further promote 
insulin resistance, particularly in skeletal muscle and in the 
liver. Muscle cells require more insulin than normal to clear 
excess glucose from the blood, while in the liver normal levels 
of insulin fail to suppress adequately the release of glucose 
into the bloodstream.4,6,7 To compensate for insulin resistance, 
pancreatic β-cells produce extra insulin, resulting in elevated 
blood insulin levels. Frank diabetes emerges when the β-cells 
ultimately fail to compensate fully for insulin resistance.4,5
Uncontrolled diabetes sufficiently severe to produce the 
classic symptoms of excessive thirst, hunger, and   urination 
typically entails weight loss despite elevated calorie intake, as 
insulin-dependent tissues “starve in the midst of plenty” and 
the kidneys respond to severe hyperglycemia by excreting 
excess glucose in the urine. Even in the absence of symptom-
atic disease, the kidneys will excrete glucose, and thus waste 
calories, when blood glucose levels exceed the renal glucose 
threshold, typically around 180 mg/dL (10 mmol/L, Figure 1), 
although this value varies   substantially in individuals.8,9 An 
individual whose glycemic levels frequently exceed the renal 
threshold may engage in compensatory overeating to recover 
calories lost in urine. In such a patient, initiation or inten-
sification of glycemic control with an agent that increases 
insulin availability or enhances insulin action can result in 
weight gain, because glucose that otherwise would have 
been excreted is now taken up by body tissues. Reduction of 
glycosuria via improvement in glycemic control could thus 
produce weight gain.
At the other end of the glycemic spectrum (see Figure 1), 
agents capable of triggering hypoglycemic episodes can also 
promote weight gain, especially as part of an   intensified 
regimen aimed at achieving normal or near-normal   glycemic 
levels. The phenomenon was initially demonstrated in 
patients with type 1 diabetes in the Diabetes Control and 
Complications Trial, where at five years, patients randomized 
to intensive insulin therapy gained a mean of 4.6 kg more 
than those receiving conventional therapy.10 Patients in the 
intensive insulin therapy group also experienced significantly 
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Figure 1 Calorie wasting and defensive eating are possible results of fluctuating plasma glucose levels in type 2 diabetes, confounding weight management.
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more, and more severe, hypoglycemic episodes. Patients 
with type 2 diabetes participating in the United Kingdom 
Prospective Diabetes Study were randomized to intensive 
sulfonylurea or insulin therapy or to less aggressive “con-
ventional” therapy. Patients in the intensive therapy group 
experienced more hypoglycemic episodes and gained more 
weight, especially those taking insulin.11 The weight gain 
may be related in part to an increase in “defensive eating” to 
prevent a decline from normoglycemia to hypoglycemia.
Agent- and class-specific effects
Drug therapies can also influence weight balance by virtue 
of their effects on fat storage. Insulin potently inhibits lipoly-
sis in adipocytes, thus promoting intracellular triglyceride 
storage.4 In a comparative study of insulin and sulfonylurea 
therapy in patients with type 2 diabetes, Birkeland et al 
demonstrated a significant body mass increase in insulin-
treated patients, of which only 30% was attributable to lean 
body mass.12
TZD package inserts also indicate that these drugs 
promote weight gain through increases in body fat mass, 
as well as through fluid retention.13,14 In a small placebo-
controlled trial employing oral glucose tolerance tests and 
a two-step euglycemic insulin clamp technique, Miyazaki 
et al documented an increase in total body fat mass with 
rosiglitazone.15 The response correlated inversely with serum 
FFA levels and with FFA mobilization from adipocytes. 
The investigators suggested that the increased fat storage 
was partly attributable to enhanced adipocyte sensitivity to 
the antilipolytic action of endogenous insulin; additionally, 
they noted that rosiglitazone favors fat storage in peripheral 
rather than in the more lipolytically active visceral fat tissue, 
an observation corroborated for pioglitazone as well.16 The 
literature provides little concrete support for any significant 
contribution of fluid retention to the average additional 
weight gain seen with TZDs. Fewer than 10% of patients 
taking TZDs have peripheral edema.17 For instance, even if 
one-third of a 3 kg average TZD weight gain were due to 
edema, then those patients with peripheral edema (assuming 
10% of them had edema) would need to have an average of 
at least 10 kg in fluid retention. Fluid retention contributes 
to noticeable weight gain in some patients, but in our view 
most TZD-associated weight gain comes from an increase 
in fat mass.
Two classes of type 2 diabetes agents, the GLP-1 receptor 
agonists and the DPP-4 inhibitors, reduce hyperglycemia by 
mimicking or enhancing incretin actions. Incretins are hor-
mones released from the gut in response to food intake that 
increase the glucose sensitivity of pancreatic β- and α-cells.18 
The two principal incretins, GLP-1 and   glucose-dependent 
insulinotropic polypeptide (GIP), are responsible for the 
amplification of insulin secretion that occurs following an 
oral, as opposed to an equivalent intravenous, glucose load, ie, 
the incretin effect. Incretin-based pharmacotherapy improves 
glycemic control in patients with type 2 diabetes, in whom 
the incretin response is commonly impaired.19,20
Incretin hormones boost insulin secretion by β-cells only 
in the setting of rising glucose, ie, in a glucose-dependent 
manner.20 Early studies of the potential of incretin-based 
therapy, involving direct infusions of GLP-1 into both 
normal and type 2 diabetic individuals, confirmed such a 
self-limiting glucose-lowering effect.21,22 As a result, unlike 
indiscriminate insulin secretagogues, such as sulfonylureas 
and glinides, incretin-based therapies are associated with a 
rather low hypoglycemia risk and are therefore less likely to 
promote weight gain related to defensive eating.
The twice-daily injectable GLP-1 mimetic, exenatide, 
exhibits minimal risk of hypoglycemia when given as 
monotherapy.20,23 Early GLP-1 infusion studies also showed 
that at high doses the hormone increases subjective satiety 
and delays gastric emptying.24 These characteristics are also 
seen with exenatide and liraglutide therapies, which have 
been consistently demonstrated to produce weight loss in 
type 2 diabetic patients.23,25 In the six Phase III studies of the 
Liraglutide Effect and Action in Diabetes (LEAD) program, 
weight loss was observed with liraglutide treatment across all 
studies, and in LEAD-6, which directly compared liraglutide 
and exenatide, weight loss was shown to be comparable for 
both agents over 26 weeks (−3.2 kg for liraglutide, −2.9 kg 
for exenatide).26,27
DPP-4 inhibitors bind and inhibit the enzyme that cleaves 
and inactivates GLP-1 and GIP. Inhibiting the degradation 
of these short-lived hormones increases their concentration 
and prolongs their activity. In contrast with GLP-1 receptor 
agonists, DPP-4 inhibitors enhance the action of endogenous 
incretins physiologically, at the time of their secretion.18
Vildagliptin
The extensively studied DPP-4 inhibitor, vildagliptin, enhances 
β- and α-cell sensitivity to glucose, resulting in an enhanced 
postprandial insulin response and blunted glucagon secretion, 
as well as improved fasting glycemia.18,28,29 Vildagliptin’s 
mechanism of action appears to be associated with a low 
hypoglycemia risk in a wide range of settings and regimens,30–39 
and presumably with a low risk for hypoglycemia-related 
defensive eating.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Unlike exenatide, vildagliptin does not mimic infused 
GLP-1 with respect to subjective satiety or gastric volume,40 
effects which have been associated with noticeable 
weight loss. Overall weight neutrality has been seen with 
vildagliptin,1,31,32,34,37–39,41 as opposed to the weight gain seen 
with insulin and sulfonylureas.1,11
The overall weight neutrality seen with vildagliptin 
appears to be a class effect because the DPP-4 inhibitors, 
saxagliptin and sitagliptin, have also been shown to produce 
improvements in glycemic control, both as monotherapy and 
as add-on therapy to other oral agents, without significant 
change in body weight in most clinical trials.42–50
In a head-to-head randomized clinical trial in patients with 
relatively low baseline glycemic values (mean HbA1C 7.3%, 
fasting plasma glucose [FPG] 9.2 mmol/L [165 mg/dL]), 
patients inadequately controlled on metformin who were 
randomized to vildagliptin 50 mg bid were weight stable at 
52 weeks (−0.2 kg), which was highly significant compared 
with the weight gain seen in the comparator group receiving 
glimepiride #6 mg daily (between-group difference −1.8 kg, 
P , 0.001).41 This difference presumably stems in part from 
the glucose-dependent “fail-safe” system that prevents even 
elevated incretin levels from overstimulating insulin secretion 
in the absence of elevated or rising glucose levels. Perhaps 
more important, whereas vildagliptin improves the sensitivity 
of the α-cell to glucose, the sulfonylurea reduces it, leading 
to a more robust glucagon counterregulatory response with 
vildagliptin.51
Additionally, the severity of baseline hyperglycemia, and 
the degree to which it may be accompanied by glycosuria, 
likely modulates the subsequent influence of vildagliptin on 
weight in clinical trials. Thus, baseline glycemic levels that 
frequently or chronically exceed the renal glucose threshold 
can confound weight balance in patients with diabetes. 
Mean baseline HbA1C levels in the majority of vildagliptin 
monotherapy and add-on trials usually exceeded 8%, cor-
responding to an estimated average glucose of 183 mg/dL.52 
Baseline fasting plasma glucose levels also tended to meet 
or exceed the typical renal threshold. Vildagliptin treatment 
was weight neutral or associated with only small increases in 
weight across these clinical trials. In one placebo-controlled 
trial of vildagliptin monotherapy in drug-naïve patients, 
for example, weight loss relative to baseline was seen in 
both active treatment and placebo groups.32 A slight gain in 
weight with vildagliptin monotherapy relative to placebo was 
observed in another study, although both vildagliptin and 
placebo groups showed a reduction relative to baseline.31 In 
head-to-head comparisons with rosiglitazone or metformin 
in drug-naïve patients, vildagliptin monotherapy achieved 
comparable levels of glycemic efficacy, with no changes in 
weight by the end of the studies. In contrast, patients receiving 
rosiglitazone experienced statistically significant weight gain, 
while patients receiving metformin lost weight.38,39
Reversal of renal caloric wasting as glycemic control 
improved may have offset some of the favorable weight 
effects that otherwise might have been seen with vildagliptin 
in these trials, potentially explaining the difference between 
the weight neutrality and actual weight loss. Consistent with 
this possibility, in a two-year randomized trial of vildagliptin 
monotherapy in patients with mild baseline hyperglycemia 
(HbA1C 6.6%, FPG 6.9 mmol/L [124 mg/dL]), patients 
randomized to vildagliptin achieved a mean 1.1 kg weight 
loss, which was statistically significant (P = 0.026) versus 
baseline.34
Potential novel mechanisms  
for weight neutrality
Several recently identified mechanisms may explain the 
weight neutrality, and in some cases weight loss, associated 
with vildagliptin. In a single-center, randomized trial, drug-
naïve type 2 diabetic patients randomized to vildagliptin 
(50 mg bid) or placebo underwent a fat tolerance test at base-
line and at the conclusion of a four-week follow-up period. 
The fat tolerance test entailed consumption of a standard-
ized fat-rich meal followed by assessment of multiple lipid, 
lipoprotein, and apolipoprotein parameters.53
Despite the short follow-up period and the relatively low 
mean HbA1C levels (~6.9%) at baseline, the researchers docu-
mented statistically significant reductions in HbA1C, FPG, and 
postprandial glucose with vildagliptin. In the fat tolerance 
test, vildagliptin reduced postchallenge circulating triglycer-
ide levels compared with placebo. The response appeared to 
be related to corresponding statistically significant reductions 
in chylomicron triglyceride, chylomicron cholesterol, and 
chylomicron apolipoprotein (apo) B-48 levels. Reductions in 
the constituent lipid and apolipoprotein components of other 
triglyceride-rich lipoproteins (very low-density lipoprotein, 
intermediate-density lipoprotein) did not achieve statistical 
significance.53
Since chylomicrons are the initial lipoproteins into which 
dietary triglycerides are packaged, these findings suggest 
that vildagliptin may have an inhibitory effect on fat absorp-
tion from the gut (Figure 2). This notion is consistent with 
findings in rodents, in which exogenous GLP-1 inhibited 
intestinal triglyceride absorption and GIP infusion promoted 
chylomicron triglyceride clearance. The possibility that vilda-Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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gliptin inhibits fat extraction from the gut, albeit to a lesser 
degree than a lipase inhibitor such as orlistat, constitutes a 
provocative pathway by which it may express its favorable 
weight profile.53
In another study of the effects of vildagliptin on post-
prandial metabolic parameters, Boschmann et al conducted a 
randomized, double-blind, crossover study in 20 patients with 
type 2 diabetes randomized to vildagliptin (100 mg daily) 
or placebo. On day 7, following an overnight fast, subjects 
were fitted with venous catheters and microdialysis probes 
in subcutaneous adipose tissue and skeletal muscle. Then, 
following a standardized meal, multiple lipid, endocrine, 
neuroendocrine, and metabolite factors were sampled at 
frequent intervals over the course of four hours.54
Vildagliptin augmented postprandial venous norepineph-
rine concentrations. At the same time, vildagliptin increased 
postprandial lactate and glycerol concentrations in adipose 
tissue and decreased lactate and pyruvate levels in skeletal 
muscle. These findings indicate that, contrary to the anabolic 
effects one might expect in response to incretin-enhanced 
postprandial insulin secretion, vildagliptin actually pro-
motes lipolysis in adipose tissue in the postprandial state, in 
conjunction with increased fatty acid oxidation in skeletal 
muscle. The investigators postulate that the principal impetus 
for these effects comes not from endocrine pathways but 
from sympathetic stimulation, as suggested by the elevated 
norepinephrine levels. This evidence for mobilization and 
expenditure of stored fat calories concomitant with dietary 
calorie influx provides another intriguing pathway by 
which vildagliptin may promote favorable weight balance.54 
Figure 2 provides an integrated depiction of the two pathways 
just described.
The limited mechanistic studies with other DPP-4 
inhibitors preclude a generalization of mechanistic findings 
for vildagliptin to the class of DPP-4 inhibitors as a whole. 
For instance, it is not clear that the once-daily dosing with 
saxagliptin has the same effect on GLP-1 levels as seen with 
vildagliptin 50 mg bid, and it is known that the increased 
GLP-1 levels observed at the onset of meals are maintained 
for much longer periods of time with vildagliptin than 
sitagliptin.55
Weight and insulin resistance
Clinical trial data and practical experience support a broad 
general consensus on the potential weight effects of vari-
ous type 2 diabetes drug classes and individual agents.1,2,19 
However, various confounding variables can influence these 
effects in different study cohorts or in individual patients. 
Moreover, whether a given regimen supports a “desirable” 
steady-state weight, achieves weight neutrality, or even pro-
motes significant weight loss does not in itself reliably reflect 
the status of certain underlying disease processes, eg, insulin 
resistance and β-cell dysfunction.
For example, in multiple clinical trials ranging from 24 
to 52 weeks of follow-up, exenatide was associated with 
significant weight loss as monotherapy,56 or when added to 
metformin,57,58 sulfonylurea,59 or metformin-sulfonylurea 
combination therapy.60 In all of these trials, mean BMI at 
Vildagliptin
↓ apo B-48
↑ NE
intestinal TG absorption
lipolysis
fat oxidation
FFA
Figure 2 Mechanisms that may mitigate weight gain with vildagliptin during meals. Following a high-fat meal, vildagliptin was found to reduce levels of chylomicron apo B-48, 
suggesting that it may inhibit chylomicron-mediated triglyceride absorption from the gut.53 Vildagliptin was also associated with increased postprandial catecholamine levels, 
as well as markers of lipolysis in adipose tissue and fatty acid oxidation in skeletal muscle, suggestive of sympathetically mediated lipid mobilization and catabolism in the 
postabsorptive state.54
Abbreviations: FFA, free fatty acids; Ne, norepinephrine; TG, triglyceride.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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baseline was greater than 30, ie, the National Heart Lung 
and Blood Institute’s cutoff point for “obese”. Although the 
ability of weight loss to ameliorate insulin resistance is well 
recognized,1 the one study that assessed insulin sensitivity 
(by hyperglycemic clamp) in a setting of exenatide-associated 
weight loss found that insulin sensitivity improved to the 
same degree in both exenatide- and insulin glargine-treated 
patients.57 The exenatide group experienced a mean weight 
reduction at one year of 3.6 kg, while the glargine-treated 
group gained 1 kg. The statistically significant between-
group disparity in weight control did not, as one might have 
expected, generate greater improvement in insulin sensitivity 
in the exenatide group.57
By contrast, despite more modest weight benefits in 
contrast with exenatide, vildagliptin treatment has been 
found to improve insulin sensitivity as monotherapy or as an 
add-on to metformin in a series of studies in which insulin 
sensitivity was assessed by insulin clamp,61 the oral glucose 
insulin sensitivity model,62 or frequently sampled intravenous 
glucose tolerance testing.63,64 In the clamp-assessed study, 
insulin sensitivity improved by about 15% after six weeks 
of vildagliptin therapy in a combined cohort of drug-naïve 
and metformin-treated type 2 diabetic patients.61
The reasons for these discrepancies between weight 
effects and insulin sensitivity are unclear. They may reflect 
the dynamics of caloric balance in the patients treated with 
exenatide or vildagliptin, ie, the patients who lost weight in 
the exenatide trials may have initially lost weight and then 
had a sustained period of a very small degree of positive 
caloric balance, whereas those taking vildagliptin might have 
persisted, to a very small degree, in an ongoing state of nega-
tive calorie balance despite minimal net weight change.
The improved insulin sensitivity seen after six weeks of 
vildagliptin therapy, as assessed by the euglycemic-hyperin-
sulinemic clamp described above, was also associated with 
decreased fasting lipolysis and decreased fat oxidation,61 
which is consistent with reduced stored triglyceride in non-
fat tissues. This finding supports the therapeutic potential 
of vildagliptin for ameliorating nonalcoholic fatty liver 
disease.65
Conclusions
Vildagliptin is a potent and specific DPP-4 inhibitor that has 
demonstrated weight neutrality in patients with type 2 diabe-
tes in multiple monotherapy and combination trials. The low 
risk of hypoglycemia with vildagliptin, stemming from its 
glucose-dependent mechanism of action, likely contributes to 
this weight neutrality by obviating the “defensive eating” that 
can occur with exogenous insulin or glucose-independent 
insulin secretagogues. However, additional evidence sug-
gests that vildagliptin may influence postprandial lipid and 
lipoprotein metabolism by inhibiting triglyceride absorption 
from the gut53 and/or promoting sympathetically mediated 
lipid mobilization and catabolism in the postabsorptive 
state.54 Further elaboration of these pathways could provide 
a mechanistic basis for understanding the favorable effects 
on weight associated with vildagliptin therapy. In addition, 
insulin has centrally mediated actions on hunger that could 
be attenuated by the more glucose-sensitive insulin profile 
of vildagliptin, and these have yet to be evaluated.
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